Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. - Wikidata - awgldk - TriplyDB

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q36492886

about

Cognitive enhancers for the treatment of ADHD A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)ADHD in children and adolescents.Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial.Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.Toward quality care in ADHD: defining the goals of treatment.Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.Atomoxetine's effect on societal costs in Sweden.Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics.Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.

P2860

Q22251235-5A50A335-EAF0-482B-87FB-CDA6EC01647A Q33463879-F6AC8B19-2FC3-491D-A994-583EDE053F0D Q33947402-3FEE490D-4F61-4FB5-BF25-4D68F1FAEF5C Q33988480-A2336EBF-C38A-4E14-94F3-9D502C9B4E99 Q34072167-40CD24F3-5BAF-4AA5-8B2F-642750B23DC5 Q34418781-FF0DA261-1B07-4398-B317-5F0182B33927 Q35840321-CA86768F-53EF-4B12-8BC9-5A7099020F28 Q35995076-9CF6286E-08DD-4D37-93EB-DA9E936E1941 Q36381407-6B576A63-1018-4B3E-A3CE-159CFC3E60D2 Q36746621-CFD6E96F-BC5D-4AE9-B274-90CF27E95306 Q36983210-6B9679B8-84D3-4306-A872-000BF64AA8C1 Q37248566-305AD261-53F5-4203-B140-C156F86C0CE5 Q37378254-6C44CBDA-DCE4-47A2-9FC2-4AF7B14CD3A7 Q37542382-AE57EDB2-DDA6-4427-A062-9FC317826E0C Q37960505-86BEE182-C648-4387-A3C4-3E98964E05DA Q38082894-C1EDA986-4961-48FC-A037-748A6923036B Q39213619-64CBFB4E-4FA8-4B43-A90B-2AAD4960CC59 Q42617592-CC4DDCDF-53DE-4369-BF00-496D90F6D941 Q43059421-DB027AC7-C41B-4D5F-9817-7A9A4B491D09 Q46697483-F31E7847-E396-4CE5-B57C-451F280C57BA

P2860

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q36492886

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@ast

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@en

type

label

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@ast

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@en

prefLabel

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@ast

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@en

P1433

Q36492886-F3BE7D1B-BA2C-4719-94C7-B491C8D70339

P1476

Q36492886-01A17DE0-9D50-4435-9221-C00B0224E048

P2093

Q36492886-178F1DD2-4C52-408C-87FF-B683C828E37C

Q36492886-2FC3A2C9-E5BB-406C-A468-AC9C5AFBD4EB

Q36492886-CAA29447-6085-4D2E-B99C-4B173CBEFBEA

Q36492886-ECF4F7F5-8CF2-4912-860E-3280DBB5AC03

P2860

Q36492886-00978D7C-0109-49F7-B553-D4B9F931801E

Q36492886-187F60EE-C2BF-4F83-B691-CCA396E74604

Q36492886-1F33C2BE-A2D5-4D06-9D16-D557CDFE67E7

Q36492886-21055D71-FD4E-4879-8467-A4B3E871B562

Q36492886-23DE8BAD-236D-4881-964E-2EB518CD69D1

Q36492886-28D91213-6226-4C8A-877A-E549D74DD527

Q36492886-31932385-D893-4E65-8D54-74D79700134C

Q36492886-6FDA3D98-B22B-478D-A627-88DA38985428

Q36492886-76E5142E-29A6-4789-8F85-0D3A65829847

Q36492886-7FF4D6D7-7A0E-4FF8-8ADB-52DE0DF70004

P304

Q36492886-C3B873A2-4E37-4AA6-AA8E-8C22CB6B8F56

P31

Q36492886-3E8A09A1-06ED-45B5-BC17-03B6A14B0AAF

Q36492886-d5af2ec6-890f-4f07-b527-412041ecee03

P356

Q36492886-7B100F33-7B31-4556-8469-FE3054F2F224

P407

Q36492886-F930A9CF-B1F6-4773-A977-99529B3B2EF3

P433

Q36492886-6C2190DB-8CF4-49DC-B8B0-20AC62D82BB0

P478

Q36492886-5BA208B2-A5FD-400D-94AA-0EA2365B6283

P577

Q36492886-FFB25F5F-C910-46A8-BB21-11A8D5C0787C

P698

Q36492886-59F83E1F-BA6A-41A9-B009-4CAA78155C1D

P921

Q36492886-59B38E44-42DF-41ED-8B85-B8708DDBCDD0

P356

P1433

Annals of Pharmacotherapy

P1476

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

@en

P2093

Aaron P Gibson

http://www.w3.org/2001/XMLSchema#string

M Lynn Crismon

http://www.w3.org/2001/XMLSchema#string

Nick C Patel

http://www.w3.org/2001/XMLSchema#string

Tawny L Bettinger

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.

Serum and brain concentrations of methylphenidate: implications for use and abuse.

Tourette's syndrome: are stimulants safe?

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.

Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder.

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.

P304

1134-1142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G582

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16735655

http://www.w3.org/2001/XMLSchema#string

P921